The pipeline for mantle cell lymphoma (MCL), a subtype of non-Hodgkin’s lymphoma (NHL), is relatively large and dominated by small molecule kinase inhibitors, which represent 37% of the therapies, followed by monoclonal antibodies (24%) and chimeric antigen receptor T-cell (CAR-T) therapy (18%).

The large prominence of CAR-T, a new and innovative therapy type, is due to the successful approvals that CAR-T therapies have garnered in diffuse large B-cell lymphoma (DLBCL), which is both another subtype of NHL and an indication in which Kite’s Yescarta (axicabtagene ciloleucel) and Novartis’ Kymriah (tisagenlecleucel) are already approved. Developers hope CAR-T therapy will be introduced into MCL soon, as Kymriah is already in Phase III development for the indication.

Other Phase III agents include Celgene’s Revlimid (lenalidomide) and Janssen’s Imbruvica (ibrutinib), both of which are already approved in other NHL subtypes and are seeking label expansion in MCL. Abbvie/Genentech’s Venclexta (Venetoclax) is a Phase III agent that is seeking a first approval in NHL, and is already approved in chronic lymphocytic leukemia (CLL).

The figure below displays the Phase II and III pipeline for MCL.

Picture: Phase II and III Pipeline for Mantle Cell Lymphoma, 2019. Credit: GlobalData. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.